p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p38beta2 polypeptides and polynucleotides in the design of protocols f or the treatment of central nervous system disorder such as senile dementia of the Alzh eimer's type (SDAT), mutiple sclerosis, cerebral malaria, stroke, head trauma and spinal cord injury; cardiovascular diseases such as restenosis and atherosclerosis; inflammatory dis eases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma; and other such diseases or c onditions associated with dysregulated or excess cytokines such as osteoporosis, sepsis du e to surgical or traumatic incident, chronic renal failure, AIDs, cachexia and autoimmune conditi ons such as lupus erthyromatosis, host graft rejection and graft verus host disease, among others, and diagnostic assays for such conditions.
DRUG BINDING PROTEIN